Evommune (NYSE:EVMN) Insider Gregory Moss Sells 14,223 Shares

Evommune, Inc. (NYSE:EVMN) insider Gregory Moss sold 14,223 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $22.83, for a total transaction of $324,711.09. Following the completion of the sale, the insider owned 60,835 shares of the company’s stock, valued at approximately $1,388,863.05. This represents a 18.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Evommune Trading Down 5.1%

NYSE EVMN opened at $22.04 on Tuesday. The business’s 50-day moving average is $24.12. The firm has a market cap of $793.70 million and a PE ratio of -2.32. Evommune, Inc. has a 52-week low of $13.89 and a 52-week high of $33.20.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. On average, equities analysts anticipate that Evommune, Inc. will post -2.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on EVMN. Oppenheimer began coverage on shares of Evommune in a report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 target price on the stock. Morgan Stanley boosted their target price on shares of Evommune from $54.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $48.00 target price on shares of Evommune in a research note on Friday, April 10th. Clear Str raised shares of Evommune to a “strong-buy” rating in a research note on Tuesday, March 17th. Finally, Evercore reaffirmed an “outperform” rating and set a $55.00 target price on shares of Evommune in a research note on Tuesday, February 10th. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $49.25.

Institutional Investors Weigh In On Evommune

A number of institutional investors have recently added to or reduced their stakes in EVMN. EQT Fund Management S.a r.l. bought a new stake in Evommune during the 4th quarter worth approximately $84,395,000. RA Capital Management L.P. bought a new stake in Evommune during the 4th quarter worth approximately $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC bought a new stake in Evommune during the 4th quarter worth approximately $32,989,000. Nan Fung Group Holdings Ltd bought a new stake in Evommune during the 4th quarter worth approximately $24,670,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Evommune in the 4th quarter worth approximately $22,408,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.